To further explore the importance of PPARα, we applied AAV‐mediated shRNA delivery to reduce the hepatic PPARα level, followed by the NAFLD model establishment and DhT treatment (Figure 9A). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.